Sun Pharmaceutical Industries reported a mixed set of earnings for the fourth quarter of FY25, with net profit declining 19% year-on-year to Rs 2,153.9 crore, down from Rs 2,658.7 crore in the same period last year. The drop in bottom-line performance comes despite a robust operational showing.
The company’s revenue rose 8.1% YoY to Rs 12,958.8 crore, compared to Rs 11,983 crore in Q4 FY24. Operating performance was particularly strong, with EBITDA surging 22.4% year-on-year to Rs 3,715.9 crore, up from Rs 3,035.15 crore. EBITDA margins also expanded sharply to 28.7%, compared to 25.3% in the year-ago quarter, indicating improved cost efficiency and better product mix.
Despite the dip in net profit, the company announced a final dividend of Rs 5.50 per share for its shareholders.
The sharp fall in profit could be attributed to exceptional or non-operating items, the details of which are awaited in the management commentary.
